Chiba T, Kashiwagi K, Chiba N, Tsukahara S
Department of Ophthalmology, University of Yamanashi Faculty of Medicine, 1110 Shimokato, Tamaho, Yamanashi 409-3898, Japan.
Br J Ophthalmol. 2006 Mar;90(3):314-7. doi: 10.1136/bjo.2005.080895.
To investigate the effects of a non-steroidal anti-inflammatory drug (NSAID) ophthalmic solution on latanoprost induced intraocular pressure (IOP) reduction in glaucoma patients.
Examination was conducted on 16 eyes of 16 glaucoma patients who had been given only latanoprost for at least 6 weeks. The NSAID ophthalmic solution, sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate, was additionally given for 12 weeks into one eye (NSAID group), while sodium hyaluronic acid ophthalmic solution was administered into the other eye (control group) in a double masked fashion. The IOP measurement was performed before the start of additional administration of ophthalmic solutions, 2, 4, 6, 8, 10, and 12 weeks after the start of additional administration, and 2, 4, and 6 weeks after discontinuing additional administration.
No significant difference was observed in the IOPs before additional administration of ophthalmic solution between the NSAID group and the control group. Following the additional administration of ophthalmic solution, IOP in the NSAID group was consistently higher than that in the control group, and a maximum difference in IOP between the two groups was 1.08 (SD 1.75) mm Hg (p = 0.03). This trend was observed even after additional administration was discontinued.
NSAID ophthalmic solution may partly affect IOP reduction by latanoprost.
研究一种非甾体抗炎药（NSAID）眼药水对青光眼患者使用拉坦前列素降低眼压（IOP）效果的影响。
对16例青光眼患者的16只眼睛进行检查，这些患者仅使用拉坦前列素至少6周。以双盲方式，一只眼睛额外给予NSAID眼药水2 -氨基- 3 -（4 -溴苯甲酰基）苯乙酸倍半水合物钠12周（NSAID组），另一只眼睛给予透明质酸钠眼药水（对照组）。在额外给予眼药水开始前、开始后2、4、6、8、10和12周以及停止额外给药后2、4和6周进行眼压测量。
NSAID组和对照组在额外给予眼药水前的眼压无显著差异。额外给予眼药水后，NSAID组的眼压始终高于对照组，两组眼压的最大差异为1.08（标准差1.75）mmHg（p = 0.03）。即使在停止额外给药后，这种趋势仍然存在。
NSAID眼药水可能会部分影响拉坦前列素降低眼压的效果。
